247 related articles for article (PubMed ID: 26270767)
1. A semiquantitative metric for evaluating clinical actionability of incidental or secondary findings from genome-scale sequencing.
Berg JS; Foreman AK; O'Daniel JM; Booker JK; Boshe L; Carey T; Crooks KR; Jensen BC; Juengst ET; Lee K; Nelson DK; Powell BC; Powell CM; Roche MI; Skrzynia C; Strande NT; Weck KE; Wilhelmsen KC; Evans JP
Genet Med; 2016 May; 18(5):467-75. PubMed ID: 26270767
[TBL] [Abstract][Full Text] [Related]
2. A standardized, evidence-based protocol to assess clinical actionability of genetic disorders associated with genomic variation.
Hunter JE; Irving SA; Biesecker LG; Buchanan A; Jensen B; Lee K; Martin CL; Milko L; Muessig K; Niehaus AD; O'Daniel J; Piper MA; Ramos EM; Schully SD; Scott AF; Slavotinek A; Sobreira N; Strande N; Weaver M; Webber EM; Williams MS; Berg JS; Evans JP; Goddard KA
Genet Med; 2016 Dec; 18(12):1258-1268. PubMed ID: 27124788
[TBL] [Abstract][Full Text] [Related]
3. Evidence-based assessments of clinical actionability in the context of secondary findings: Updates from ClinGen's Actionability Working Group.
Webber EM; Hunter JE; Biesecker LG; Buchanan AH; Clarke EV; Currey E; Dagan-Rosenfeld O; Lee K; Lindor NM; Martin CL; Milosavljevic A; Mittendorf KF; Muessig KR; O'Daniel JM; Patel RY; Ramos EM; Rego S; Slavotinek AM; Sobriera NLM; Weaver MA; Williams MS; Evans JP; Goddard KAB;
Hum Mutat; 2018 Nov; 39(11):1677-1685. PubMed ID: 30311382
[TBL] [Abstract][Full Text] [Related]
4. An Age-Based Framework for Evaluating Genome-Scale Sequencing Results in Newborn Screening.
Milko LV; O'Daniel JM; DeCristo DM; Crowley SB; Foreman AKM; Wallace KE; Mollison LF; Strande NT; Girnary ZS; Boshe LJ; Aylsworth AS; Gucsavas-Calikoglu M; Frazier DM; Vora NL; Roche MI; Powell BC; Powell CM; Berg JS
J Pediatr; 2019 Jun; 209():68-76. PubMed ID: 30851990
[TBL] [Abstract][Full Text] [Related]
5. Return of non-ACMG recommended incidental genetic findings to pediatric patients: considerations and opportunities from experiences in genomic sequencing.
Bowling KM; Thompson ML; Kelly MA; Scollon S; Slavotinek AM; Powell BC; Kirmse BM; Hendon LG; Brothers KB; Korf BR; Cooper GM; Greally JM; Hurst ACE
Genome Med; 2022 Nov; 14(1):131. PubMed ID: 36414972
[TBL] [Abstract][Full Text] [Related]
6. Secondary findings from next-generation sequencing: what does actionable in childhood really mean?
Richer J; Laberge AM
Genet Med; 2019 Jan; 21(1):124-132. PubMed ID: 29875419
[TBL] [Abstract][Full Text] [Related]
7. Defining categories of actionability for secondary findings in next-generation sequencing.
Moret C; Mauron A; Fokstuen S; Makrythanasis P; Hurst SA
J Med Ethics; 2017 May; 43(5):346-349. PubMed ID: 28039284
[TBL] [Abstract][Full Text] [Related]
8. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics.
Kalia SS; Adelman K; Bale SJ; Chung WK; Eng C; Evans JP; Herman GE; Hufnagel SB; Klein TE; Korf BR; McKelvey KD; Ormond KE; Richards CS; Vlangos CN; Watson M; Martin CL; Miller DT
Genet Med; 2017 Feb; 19(2):249-255. PubMed ID: 27854360
[TBL] [Abstract][Full Text] [Related]
9. ClinGen's Pediatric Actionability Working Group: Clinical actionability of secondary findings from genome-scale sequencing in children and adolescents.
Hunter JE; Jenkins CL; Bulkley JE; Gilmore MJ; Lee K; Pak CM; Wallace KE; Buchanan AH; Foreman AKM; Freed AS; Goehringer S; Manickam K; Meeks NJL; Ramos EM; Shah N; Steiner RD; Subramanian SL; Trotter T; Webber EM; Williams MS; Goddard KAB; Powell BC;
Genet Med; 2022 Jun; 24(6):1328-1335. PubMed ID: 35341655
[TBL] [Abstract][Full Text] [Related]
10. A curated gene list for reporting results of newborn genomic sequencing.
Ceyhan-Birsoy O; Machini K; Lebo MS; Yu TW; Agrawal PB; Parad RB; Holm IA; McGuire A; Green RC; Beggs AH; Rehm HL
Genet Med; 2017 Jul; 19(7):809-818. PubMed ID: 28079900
[TBL] [Abstract][Full Text] [Related]
11. Processes and preliminary outputs for identification of actionable genes as incidental findings in genomic sequence data in the Clinical Sequencing Exploratory Research Consortium.
Berg JS; Amendola LM; Eng C; Van Allen E; Gray SW; Wagle N; Rehm HL; DeChene ET; Dulik MC; Hisama FM; Burke W; Spinner NB; Garraway L; Green RC; Plon S; Evans JP; Jarvik GP;
Genet Med; 2013 Nov; 15(11):860-7. PubMed ID: 24195999
[TBL] [Abstract][Full Text] [Related]
12. ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG).
Miller DT; Lee K; Abul-Husn NS; Amendola LM; Brothers K; Chung WK; Gollob MH; Gordon AS; Harrison SM; Hershberger RE; Klein TE; Richards CS; Stewart DR; Martin CL;
Genet Med; 2023 Aug; 25(8):100866. PubMed ID: 37347242
[TBL] [Abstract][Full Text] [Related]
13. Frequency and management of medically actionable incidental findings from genome and exome sequencing data: a systematic review.
Elfatih A; Mohammed I; Abdelrahman D; Mifsud B
Physiol Genomics; 2021 Sep; 53(9):373-384. PubMed ID: 34250816
[TBL] [Abstract][Full Text] [Related]
14. Expert and lay perspectives on burden, risk, tolerability, and acceptability of clinical interventions for genetic disorders.
Paquin RS; Mittendorf KF; Lewis MA; Hunter JE; Lee K; Berg JS; Williams MS; Goddard KAB
Genet Med; 2019 Nov; 21(11):2561-2568. PubMed ID: 31028355
[TBL] [Abstract][Full Text] [Related]
15. ACMG SF v3.1 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG).
Miller DT; Lee K; Abul-Husn NS; Amendola LM; Brothers K; Chung WK; Gollob MH; Gordon AS; Harrison SM; Hershberger RE; Klein TE; Richards CS; Stewart DR; Martin CL;
Genet Med; 2022 Jul; 24(7):1407-1414. PubMed ID: 35802134
[No Abstract] [Full Text] [Related]
16. Actionability of unanticipated monogenic disease risks in newborn genomic screening: Findings from the BabySeq Project.
Green RC; Shah N; Genetti CA; Yu T; Zettler B; Uveges MK; Ceyhan-Birsoy O; Lebo MS; Pereira S; Agrawal PB; Parad RB; McGuire AL; Christensen KD; Schwartz TS; Rehm HL; Holm IA; Beggs AH;
Am J Hum Genet; 2023 Jul; 110(7):1034-1045. PubMed ID: 37279760
[TBL] [Abstract][Full Text] [Related]
17. Frequency and spectrum of actionable pathogenic secondary findings in 196 Korean exomes.
Jang MA; Lee SH; Kim N; Ki CS
Genet Med; 2015 Dec; 17(12):1007-11. PubMed ID: 25856671
[TBL] [Abstract][Full Text] [Related]
18. Perspectives of clinical genetics professionals toward genome sequencing and incidental findings: a survey study.
Lemke AA; Bick D; Dimmock D; Simpson P; Veith R
Clin Genet; 2013 Sep; 84(3):230-6. PubMed ID: 23163796
[TBL] [Abstract][Full Text] [Related]
19. Differences in Conceptual Understanding of the "Actionability" of Incidental Findings and the Resultant Difference in Ethical Responsibility: An Empirical Study in Japan.
Ibuki T; Yamamoto K; Matsui K
AJOB Empir Bioeth; 2020; 11(3):187-194. PubMed ID: 32615058
[TBL] [Abstract][Full Text] [Related]
20. Actionability of commercial laboratory sequencing panels for newborn screening and the importance of transparency for parental decision-making.
DeCristo DM; Milko LV; O'Daniel JM; Foreman AKM; Mollison LF; Powell BC; Powell CM; Berg JS
Genome Med; 2021 Mar; 13(1):50. PubMed ID: 33781310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
